Home Cart Sign in  
Chemical Structure| 199986-75-9 Chemical Structure| 199986-75-9

Structure of CVT-313
CAS No.: 199986-75-9

Chemical Structure| 199986-75-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CVT-313 is a potent, selective, ATP-competitive and reversible inhibitor of CDK2 with IC50 of 0.5 μM for Cdk2/A and Cdk2/E; 4.2 μM for Cdk1/B; 215 μM for Cdk4/D1.

Synonyms: Cdk2 Inhibitor III; Cyclin-dependent kinase 2 Inhibitor III

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CVT-313

CAS No. :199986-75-9
Formula : C20H28N6O3
M.W : 400.47
SMILES Code : COC1=CC=C(C=C1)CNC2=C3N=CN(C(C)C)C3=NC(N(CCO)CCO)=N2
Synonyms :
Cdk2 Inhibitor III; Cyclin-dependent kinase 2 Inhibitor III
MDL No. :MFCD06411412
InChI Key :NQVIIUBWMBHLOZ-UHFFFAOYSA-N
Pubchem ID :6918386

Safety of CVT-313

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of CVT-313

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CRC119 IC50 7.6 μM 48 hours Evaluate the inhibitory effect of CVT-313 on CRC119 cells, IC50 7.6 μM PMC7718319
AsPC-1 2.5–80 μM 16 hours To evaluate the effect of CVT-313 on CHK1i monotherapy-induced γH2AX and S phase arrest. PMC7088890
CRC16-159 IC50 7.6 μM 48 hours Evaluate the inhibitory effect of CVT-313 on CRC16-159 cells, IC50 7.6 μM PMC7718319
CRC401 IC50 7.6 μM 48 hours Evaluate the inhibitory effect of CVT-313 on CRC401 cells, IC50 7.6 μM PMC7718319
CRC247 IC50 7.6 μM 48 hours Evaluate the inhibitory effect of CVT-313 on CRC247 cells, IC50 7.6 μM PMC7718319
CRC240 IC50 7.6 μM 48 hours Evaluate the inhibitory effect of CVT-313 on CRC240 cells, IC50 7.6 μM PMC7718319
CRC057 IC50 7.6 μM 48 hours Evaluate the inhibitory effect of CVT-313 on CRC057 cells, IC50 7.6 μM PMC7718319
MDA-MB-231 1 μM 24 hours To evaluate the effect of CVT-313 on CHK1i- or WEE1i-mediated S phase progression. PMC7088890
COS-7 cells 1 μM 3 hours Inhibition of CDC5L phosphorylation PMC2940709
C127 mammary carcinoma cells 25 μM 24 hours Inhibits cdk2 activity and blocks histone H1 phosphorylation PMC87264
1471.1 cells 10 μM and 25 μM 24 hours To investigate the effects of CVT-313 on the phosphorylation of mouse H1.3 and H1.4 histone isoforms, results showed that CVT-313 significantly reduced the phosphorylation levels of H1.3 and H1.4. PMC2761089
UL3 cells 10 μM and 25 μM 24 hours To determine the effects of CVT-313 on the phosphorylation of human H1.2 and H1.4 histone isoforms, results showed that CVT-313 significantly reduced the phosphorylation levels of H1.2 and H1.4. PMC2761089

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID mice CRC240 PDX model Intraperitoneal injection 0.625 mg/kg Every other day for 14 days Evaluate the inhibitory effect of CVT-313 alone or in combination with LDC067 on CRC240 PDX tumor growth, combination therapy showed synergistic effects PMC7718319
C57BL/6 mice Ovarian cancer model Intraperitoneal injection 20 mg/kg Consecutive 12 days, with a break of 1 day every 4 days of treatment CVT-313 significantly reduced the tumor volume and the abundance of macrophages in ascites and enhanced the tumor sensitivity to anti-PD-1 therapy PMC10590509
Mouse In vitro culture 25 μM 24 hours Inhibits histone H1 phosphorylation and blocks GR-mediated chromatin remodeling and activation of the MMTV promoter PMC87264

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.50mL

0.50mL

0.25mL

12.49mL

2.50mL

1.25mL

24.97mL

4.99mL

2.50mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories